SSTR5 and acromegaly: In the study by Coopmans et al20 that included 45 acromegaly patients who were previously treated with first-generation SSAs combined with pegvisomant, SSTR2 immunoreactivity scores were found to be related to significant tumor shrinkage in patients treated with pasireotide, which was not the case for SSTR5.